Targeting high mobility group box 1 as a late-acting mediator of inflammation.

Sepsis, a lethal systemic inflammatory response to infection, affects nearly 750,000 patients in the United States annually and has a mortality of 30%. Mounting evidence has implicated cytokines, circulating factors produced by the innate immune system, as critical mediators of sepsis-related tissue injury and death. Many resources have been expended to elucidate the pathologic mechanisms that underlie sepsis and to develop appropriate and effective therapeutics. To date, no anti-inflammatory agent has been clinically approved for the treatment of sepsis because even a slight delay in administration of therapeutics that target inflammatory mediators renders most approaches ineffective. These and other findings, described in part in this review, suggest that successful clinical management of sepsis may be dependent on identification of late-acting, downstream lethal mediators that can be targeted in a broader therapeutic window. A candidate mediator of delayed lethality is high mobility group box 1, a cellular and nuclear protein that is now recognized as a cytokine and experimental therapeutic target.

[1]  M. Gariboldi,et al.  Mapping of the Hmg1 gene and of seven related sequences in the mouse , 1995, Mammalian Genome.

[2]  Kevin J. Tracey,et al.  The inflammatory reflex , 2002, Nature.

[3]  Jun Yu Li,et al.  High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. , 2002, Arthritis and rheumatism.

[4]  M. Bianchi,et al.  The nuclear protein HMGB1 is secreted by monocytes via a non‐classical, vesicle‐mediated secretory pathway , 2002, EMBO reports.

[5]  M. Bustin.  At the Crossroads of Necrosis and Apoptosis: Signaling to Multiple Cellular Targets by HMGB1 , 2002, Science's STKE.

[6]  K. Tracey,et al.  Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[7]  K. Tracey,et al.  HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. , 2002, Gastroenterology.

[8]  T. Misteli,et al.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2002, Nature.

[9]  M. Fink,et al.  Ethyl pyruvate modulates inflammatory gene expression in mice subjected to hemorrhagic shock. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[10]  M. Fink,et al.  Resuscitation from Hemorrhagic Shock with Ringer's Ethyl Pyruvate Solution Improves Survival And Ameliorates Intestinal Mucosal Hyperpermeability in Rats , 2002, Shock.

[11]  K. Tracey,et al.  HMGB-1, a DNA-binding protein with cytokine activity, induces brain TNF and IL-6 production, and mediates anorexia and taste aversion. , 2002, Cytokine.

[12]  M. Fink.  Reactive oxygen species as mediators of organ dysfunction caused by sepsis, acute respiratory distress syndrome, or hemorrhagic shock: potential benefits of resuscitation with Ringer's ethyl pyruvate solution , 2002, Current opinion in clinical nutrition and metabolic care.

[13]  H. Freeze,et al.  N‐Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth , 2002, Journal of neurochemistry.

[14]  K. Tracey,et al.  HMGB1 as a late mediator of lethal systemic inflammation. , 2001, American journal of respiratory and critical care medicine.

[15]  S. Müller,et al.  The double life of HMGB1 chromatin protein: architectural factor and extracellular signal , 2001 .

[16]  K. Tracey,et al.  Dual roles for HMGB1: DNA binding and cytokine , 2001, Journal of endotoxin research.

[17]  M. Fink,et al.  Ringer’s ethyl pyruvate solution ameliorates ischemia/reperfusion-induced intestinal mucosal injury in rats , 2001, Critical care medicine.

[18]  K. Tracey,et al.  THE HMG B BOX CONFERS CYTOKINE ACTIVITY AND SIGNALS VIA RAGE.: 79 , 2001 .

[19]  K. Tracey,et al.  HMG‐1 REDISCOVERED AS A CYTOKINE , 2001, Shock.

[20]  S. Müller,et al.  The High Mobility Group (Hmg) Boxes of the Nuclear Protein Hmg1 Induce Chemotaxis and Cytoskeleton Reorganization in Rat Smooth Muscle Cells , 2001, The Journal of cell biology.

[21]  M. Bustin.  Revised nomenclature for high mobility group (HMG) chromosomal proteins. , 2001, Trends in biochemical sciences.

[22]  L. Borrmann,et al.  Regulation of the expression of HMG1, a co-activator of the estrogen receptor. , 2001, Anticancer research.

[23]  K. Tracey,et al.  Cutting Edge: HMG-1 as a Mediator of Acute Lung Inflammation1 , 2000, The Journal of Immunology.

[24]  K. Tracey,et al.  High Mobility Group 1 Protein (Hmg-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes , 2000, The Journal of experimental medicine.

[25]  K. Tracey,et al.  Increased serum concentrations of high-mobility-group protein 1 in haemorrhagic shock , 1999, The Lancet.

[26]  K. Tracey,et al.  Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. , 1999, Surgery.

[27]  K. Tracey,et al.  HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.

[28]  H. Huttunen,et al.  Receptor for Advanced Glycation End Products (RAGE)-mediated Neurite Outgrowth and Activation of NF-κB Require the Cytoplasmic Domain of the Receptor but Different Downstream Signaling Pathways* , 1999, The Journal of Biological Chemistry.

[29]  A. Aguzzi,et al.  The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice , 1999, Nature Genetics.

[30]  I. Chaudry,et al.  Melatonin administration following hemorrhagic shock decreases mortality from subsequent septic challenge. , 1996, The Journal of surgical research.

[31]  M. Rocchi,et al.  The active gene that encodes human high mobility group 1 protein (HMG1) contains introns and maps to chromosome 13. , 1996, Genomics.

[32]  R. Reeves,et al.  High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. , 1996, Progress in nucleic acid research and molecular biology.

[33]  J. Chen,et al.  The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin , 1995, The Journal of Biological Chemistry.

[34]  H. Rauvala,et al.  Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. , 1993, The Journal of biological chemistry.

[35]  K. O. Elliston,et al.  Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. , 1992, The Journal of biological chemistry.

[36]  H. Rauvala,et al.  Interactions of plasminogen and tissue plasminogen activator (t-PA) with amphoterin. Enhancement of t-PA-catalyzed plasminogen activation by amphoterin. , 1991, The Journal of biological chemistry.

[37]  M. Daston,et al.  Expression of P30, a protein with adhesive properties, in Schwann cells and neurons of the developing and regenerating peripheral nerve , 1991, The Journal of cell biology.

[38]  M. Beltrame,et al.  Specific recognition of cruciform DNA by nuclear protein HMG1. , 1989, Science.

[39]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[40]  H. Rauvala,et al.  Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. , 1987, The Journal of biological chemistry.

[41]  J. D. Albert,et al.  Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. , 1987, Surgery, gynecology & obstetrics.

[42]  J. D. Albert,et al.  Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.

[43]  G. Goodwin,et al.  A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. , 1973, European journal of biochemistry.